The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for PRAME TCR/IL-15 NK (SY-307), an engineered T cell receptor natural killer (TCR NK) cell therapy for relapsed/refractory myeloid malignancies. MD Anderson is the IND sponsor.
PRAME TCR/IL-15 NK (SY-307) is being developed...
A national study led by researchers at The University of Texas MD Anderson Cancer Center and The University of New Mexico (UNM) Comprehensive...
The University of Texas MD Anderson Cancer Center and RUSH University System for Health today announced a partnership to create RUSH MD Anderson...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson offer insights into a novel targeted therapy for rare cancers,...
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed...
HOUSTON ― In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of...
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ABSTRACTS CT037, CT038, CT042
Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson...
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients...
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with...
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary...
ABSTRACTS: 1212, 1227, 1244, 1283, CT030, 3893, 3922, 3930, 3942, 6620
The University of Texas MD Anderson Cancer Center’s Research...
Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer...
Two researchers from The University of Texas MD Anderson Cancer Center will be honored with Scientific Achievement Awards at the American...
Padmanee Sharma, M.D., Ph.D., associate vice president of Immunobiology, professor of Genitourinary Medical Oncology and Immunology, and director...